Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
У пациентов с дифференцированным раком щитовидной железы в России появилась возможность лечиться новым препаратом Ленвима® (ленватиниб), зарегистрированным для терапии распространенной формы заболевания
У пациентов с дифференцированным раком щитовидной железы в России появилась возможность лечиться новым препаратом Ленвима® (ленватиниб), зарегистрированным для терапии распространенной формы заболевания
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Пресс-релиз
Полный текст
Список литературы
1. Инструкция по медицинскому применению препарата Ленвима®: РУ ЛП-003398 от 29.12.2015 / Instruktsiia po meditsinskomu primeneniiu preparata LenvimaR: RU LP-003398 ot 29.12.2015 [in Russian]
2. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii110-vii119.
3. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893–917.
4. Thyroid Cancer Basics. 2011. www.thyca.org
5. National Cancer Institute. Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page7
6. Cooper DS et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11): 1167–214.
7. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91 (1): 313–9.
8. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med 2014; 39 (9): 784–90.
9. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892–9.
10. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505.
11. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621–30.
2. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii110-vii119.
3. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893–917.
4. Thyroid Cancer Basics. 2011. www.thyca.org
5. National Cancer Institute. Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page7
6. Cooper DS et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11): 1167–214.
7. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91 (1): 313–9.
8. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med 2014; 39 (9): 784–90.
9. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892–9.
10. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505.
11. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621–30.
2. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii110-vii119.
3. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893–917.
4. Thyroid Cancer Basics. 2011. www.thyca.org
5. National Cancer Institute. Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page7
6. Cooper DS et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11): 1167–214.
7. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91 (1): 313–9.
8. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med 2014; 39 (9): 784–90.
9. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892–9.
10. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505.
11. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621–30.
________________________________________________
2. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii110-vii119.
3. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893–917.
4. Thyroid Cancer Basics. 2011. www.thyca.org
5. National Cancer Institute. Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page7
6. Cooper DS et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11): 1167–214.
7. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91 (1): 313–9.
8. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med 2014; 39 (9): 784–90.
9. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892–9.
10. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505.
11. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621–30.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.